SCHEMBL29616587

SCHEMBL29616587

COC(=O)[C@H](CC1CC1)NC(=O)OCc1c(F)cccc1F

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 1/20 0.46
CNR2 P34972 3/20 0.43
CTSL P07711 3/20 0.41
CTSB P07858 2/20 0.41
CTSK P43235 2/20 0.41
CTSS P25774 1/20 0.41
MMP1 P03956 2/20 0.40
MMP2 P08253 2/20 0.40
MMP9 P14780 1/20 0.40
MMP12 P39900 1/20 0.40
KYNU Q16719 1/20 0.39
AAK1 Q2M2I8 1/20 0.39
ALDH1A1 P00352 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
ALOX15 P16050 1/20 0.37
CYP3A4 P08684 1/20 0.36
TSHR P16473 1/20 0.36
AGTR2 P50052 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29662829 0.89 TGM2 (0.54) TGM2CTSLCTSBCTSKCTSS
SCHEMBL7469120 0.81 CTSK (0.59) CTSLCTSBCTSKCTSSKYNU
SCHEMBL30764688 0.81 CTSK (0.59) CTSLCTSBCTSKCTSSKYNU
SCHEMBL6987757 0.76 HDAC6 (0.51) CNR2CTSLCTSBCTSKCTSS
Ether SCHEMBL29144591 0.76 CTSK (0.54) CTSLCTSBCTSKCTSSKYNU
SCHEMBL24754583 0.75 MEN1 (0.50) CNR2ALDH1A1NPC1RAB9A
SCHEMBL30140798 0.75 MEN1 (0.50) CNR2ALDH1A1NPC1RAB9A
SCHEMBL2396971 0.74 ALDH1A1 (0.57) CTSLCTSBCTSKCTSSKYNU
SCHEMBL2396973 0.74 ALDH1A1 (0.57) CTSLCTSBCTSKCTSSKYNU
SCHEMBL18803800 0.74 ITGB3 (0.57) CTSLCTSBCTSKCTSSKYNU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540141-B2 Spiropyrrolidine derived antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2026-02-03 US disclosed
US-20230103494-A1 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2023-04-06 US disclosed
WO-2022109363-A1 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. (US) 2022-05-27 WO disclosed
EP-4001279-A1 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS Enanta Pharmaceuticals, Inc. (US) 2022-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103494-A1 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ACE, ACE2, REN TGM2 4430/4885CNR2 3036/4885CTSL 663/4885
US-12540141-B2 Spiropyrrolidine derived antiviral agents ACE2, NR3C2, ACE TGM2 4284/4885CNR2 681/4885CTSL 369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.